Association between metabolic dysfunction-associated steatotic liver disease and atherosclerotic cardiovascular disease in a tertiary care hospital: A cross-sectional study
Journal of Family and Community Medicine · 2026-10 · 33 (4) · 252-257
DOI: 10.4103/jfcm.jfcm_209_26 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Journal of Family and Community Medicine, online erschienen am 22.10.2026. Verfasst von Reem K. AlManea und 5 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Obesity, diabetes, and metabolic syndrome are becoming increasingly prevalent in Saudi Arabia, and therefore, raising concerns about metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic steatohepatitis (MASH), and related cardiovascular complications. This study compared the occurrence of atherosclerotic cardiovascular disease (ASCVD) and calculated risk scores in patients with MASLD or MASH versus those with no imaging evidence of hepatic steatosis (“Healthy Liver” group). MATERIALS AND METHODS: We retrospectively reviewed medical records of adults aged ≥18 years who had undergone abdominal imaging, including ultrasound, computed tomography, or magnetic resonance imaging between 2018 and 2022 at a tertiary care hospital in Riyadh. Data extracted included demographic characteristics, medical history, laboratory results, and results of imagaing reports. Data was analyzed using Stata; Fisher's exact test was used to test for association between liver health status and ASCVD events whereas t-test compared ASCVD risk scores between groups. RESULTS: The study included 532 patients with a mean age of 53.5 years, most of whom were women (64.3%), Saudi nationals (78.0%), and overweight or obese (50.4%). Common comorbidities found in them included dyslipidemia (42.9%), hypertension (35.2%), diabetes (34.2%), and hypothyroidism (21.4%). Frequently prescribed medications were statins (39.5%), antihypertensive agents (36.1%), and antidiabetic therapies (38.9%). All 14 documented ASCVD events occurred in patients with MASLD or MASH, while no events were observed in individuals with healthy livers ( P = 0.0001). However, 5-year and 10-year ASCVD risk scores did not differ significantly between groups. CONCLUSION: The ASCVD events were observed exclusively in MASLD/MASH patients, suggesting a potential association. Given the small event burden and retrospective design, findings are exploratory. Locally relevant Saudi data highlight the need for larger prospective studies to validate cardiovascular implications of fatty liver disease.
Zitieren
APA
AlManea, R. K., El-Abd, K., Alsinan, S. H., Alrakban, A., AlTannir, D., & Daher, D. (2026). Association between metabolic dysfunction-associated steatotic liver disease and atherosclerotic cardiovascular disease in a tertiary care hospital: A cross-sectional study. Journal of Family and Community Medicine, 33(4), 252-257. https://doi.org/10.4103/jfcm.jfcm_209_26
Vancouver
AlManea RK, El-Abd K, Alsinan SH, Alrakban A, AlTannir D, Daher D. Association between metabolic dysfunction-associated steatotic liver disease and atherosclerotic cardiovascular disease in a tertiary care hospital: A cross-sectional study. Journal of Family and Community Medicine. 2026;33(4):252-257. doi:10.4103/jfcm.jfcm_209_26
BibTeX
@article{AlManea2026,
author = {AlManea, Reem K. and El-Abd, Kossay and Alsinan, Sara H. and Alrakban, Alanoud and AlTannir, Dana and Daher, Dana},
title = {Association between metabolic dysfunction-associated steatotic liver disease and atherosclerotic cardiovascular disease in a tertiary care hospital: A cross-sectional study},
journal = {Journal of Family and Community Medicine},
year = {2026},
volume = {33},
number = {4},
pages = {252--257},
doi = {10.4103/jfcm.jfcm_209_26}
}
EUVIMED